Benetti G P, Illeni M T, Passera A, Bombelli G, Lavecchia G, Uslenghi C
1st Medical Department, Predabissi Hospital, Milan, Italy.
Arzneimittelforschung. 1994 Dec;44(12A):1503-5.
The aim of this study was to evaluate the activity of pidotimod ((R)-3-[(S)-(5-oxo-2-pyrrolidinyl)carbonyl]-thiazolidine-4-carboxylic acid, PGT/1A, CAS 121808-62-6) on 52 patients affected with chronic obstructive pulmonary disease (COPD). The study was carried out in a randomized, parallel, double-blind trial, followed by incomplete blocks design. Pidotimod 800 mg was administered orally twice a day for 30 days. The follow-up period was 5 weeks. Our results show that in patients with COPD pidotimod potentiates T-cell activity. The effects on T-cells appear after 15 days of treatment and last for 5 weeks after the end of therapy. Since other studies demonstrated that pidotimod displays an immunopotentiating activity also on macrophages and granulocytes, the drug is useful to increase the immune defense during infections. The drug has a good compliance and is well tolerated also during long-term treatment.
本研究旨在评估匹多莫德（(R)-3-[(S)-(5-氧代-2-吡咯烷基)羰基]-噻唑烷-4-羧酸，PGT/1A，CAS 121808-62-6）对52例慢性阻塞性肺疾病（COPD）患者的疗效。该研究采用随机、平行、双盲试验，并采用不完全区组设计。匹多莫德800 mg，每日口服两次，共30天。随访期为5周。我们的结果表明，在COPD患者中，匹多莫德可增强T细胞活性。对T细胞的影响在治疗15天后出现，并在治疗结束后持续5周。由于其他研究表明匹多莫德对巨噬细胞和粒细胞也具有免疫增强活性，因此该药物有助于在感染期间增强免疫防御。该药物具有良好的依从性，在长期治疗中也耐受性良好。
